SLXN (Silexion Therapeutics) EV-to-Revenue : (As of Apr. 25, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Silexion Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Silexion Therapeutics's enterprise value is $12.52 Mil. Silexion Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil. Therefore, Silexion Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Silexion Therapeutics's EV-to-Revenue or its related term are showing as below:

SLXN's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.75
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-04-25), Silexion Therapeutics's stock price is $0.93. Silexion Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00. Therefore, Silexion Therapeutics's PS Ratio for today is .

Silexion Therapeutics EV-to-Revenue Historical Data

The historical data trend for Silexion Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silexion Therapeutics EV-to-Revenue Chart

Silexion Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

EV-to-Revenue

Silexion Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EV-to-Revenue	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Silexion Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Silexion Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silexion Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silexion Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Silexion Therapeutics's EV-to-Revenue falls into.

Save Embed

;

Save Embed

;

Silexion Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Silexion Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	12.518	/	0
	=

Silexion Therapeutics's current Enterprise Value is $12.52 Mil.
Silexion Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Silexion Therapeutics (NAS:SLXN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Silexion Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.93	/	0
	=

Silexion Therapeutics's share price for today is $0.93.
Silexion Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Silexion Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Silexion Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Silexion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silexion Therapeutics Corp (NAS:SLXN) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Abba Hillel Road, Ramat-Gan, ISR, 5250606

Website

https://silexion.com

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.